Philips spends big in-house while Becton favours buying
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
Biopharma takeovers show quantity, if not quality
Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.
Chinook marks an ignominious end for Sting
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
Alexion goes in a new direction with $1.4bn Portola buy
Alexion’s move on the anticoagulant reversal specialist is not the most intuitive deal – but is 2020’s second biggest so far.
Biopharma acquisitions slow, but it's not Covid-19's fault yet
Drug makers struck few M&A deals in the first quarter, but activity did not dry up, suggesting that the real impact of coronavirus has yet to play out.
A thoroughly average year for medtech mergers
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.
Lilly jumps the gun with Dermira deal
The $1.1bn that Lilly is paying for lebrikizumab looks low ball, but competing against Dupixent will not come cheap. And then there are the Roche payments.
A big finish confirms 2019 as a takeover year to remember
Two megamergers meant that 2019 was always going to be a big year for biopharma M&A in dollar terms – and then came a late flurry of deals.
